WO2020067389A1 - 抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬 - Google Patents
抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬 Download PDFInfo
- Publication number
- WO2020067389A1 WO2020067389A1 PCT/JP2019/038066 JP2019038066W WO2020067389A1 WO 2020067389 A1 WO2020067389 A1 WO 2020067389A1 JP 2019038066 W JP2019038066 W JP 2019038066W WO 2020067389 A1 WO2020067389 A1 WO 2020067389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thrombomodulin
- oxaliplatin
- treatment
- administration
- amino acid
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/366—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
Definitions
- the present invention relates to a medicament having a symptom-reducing and / or onset-suppressing effect on peripheral neuropathy caused by an antineoplastic agent.
- antineoplastic drugs used in cancer chemotherapy have cytotoxicity and cytotoxicity, and cause side effects by damaging not only cancer cells but also normal cells.
- antineoplastic agents include hematologic toxicity, gastrointestinal disorders, and peripheral neuropathy.
- Peripheral neuropathy caused by antineoplastic agents includes pain such as severe pain or burning pain, numbness in the extremities, dysesthesia such as hypersensitivity to cold stimulation, dysesthesia such as loss of sensation or numbness, sensory ataxia, and muscle strength. And the like appear as symptoms.
- Oxaliplatin is an example of an antineoplastic agent that easily induces these peripheral neuropathies (Non-Patent Document 1).
- Non-Patent Documents 1 and 2 guidelines for the prevention and treatment of peripheral neuropathy by antineoplastic agents have been published. Only duloxetine is recommended as a treatment, and none is recommended as a suppressive drug.
- thrombomodulin is known as a substance that specifically binds to thrombin and inhibits the blood coagulation activity of thrombin, and at the same time has a function of significantly promoting the ability of thrombin to activate protein C, and has a strong blood coagulation inhibitory action. It is known (Non-Patent Document 4).
- a therapeutic agent for generalized intravascular coagulation (DIC) containing human soluble thrombomodulin as an active ingredient has been approved as a pharmaceutical in Japan as Lycomodulin (registered trademark) (Non-Patent Document 4).
- Other uses of thrombomodulin include severe sepsis, liver damage, and pain associated with hematopoietic cell transplantation (Patent Documents 2 to 4). Further, as a use of thrombomodulin, peripheral neuropathic pain caused by an anticancer drug is described (Patent Document 4).
- the problem to be solved by the present invention is to reduce the symptom and / or onset of peripheral neuropathy induced by administration of an anti-neoplastic agent in a human cancer patient undergoing anti-neoplastic treatment with oxaliplatin.
- An object of the present invention is to provide an effective and safe medicine having an inhibitory effect.
- Patent Document 4 It is known that thrombomodulin is effective for peripheral neuropathic pain caused by anticancer drugs (Patent Document 4).
- Patent Document 4 the intraperitoneal administration of thrombomodulin for 7 days on a daily basis using a rat model in which peripheral neuropathy is caused by multiple administrations of an anticancer agent has no effect on peripheral neuropathic pain caused by the anticancer agent. It merely qualitatively describes what happened.
- Patent Document 4 exemplarily describes that TMD123 (for example, Lycomodulin (registered trademark)) is administered three times immediately before, during, and immediately after administration of an anticancer agent in each course.
- TMD123 for example, Lycomodulin (registered trademark)
- thrombomodulin Although there is a general description of the number of times of administration of thrombomodulin, there is no description about administering thrombomodulin once per cycle on the first day of each cycle of antineoplastic treatment with oxaliplatin. In addition, in human cancer patients who receive anti-cancer treatment with oxaliplatin, it is effective and safe to administer thrombomodulin to human cancer patients at any dosage to suppress the development of peripheral neuropathy caused by antineoplastic agents No information was reported indicating whether the drug could be administered.
- the present invention includes the following.
- This treatment is repeated as one cycle of intravenous administration to a human cancer patient and then withdrawing from the treatment, and thrombomodulin 0.06 mg / kg intravenously once per cycle on the first day of each cycle of the antineoplastic treatment.
- the medicament comprising as an active ingredient thrombomodulin for intravenously administering 0.06 mg / kg of thrombomodulin once per cycle on the first day of each cycle of treatment.
- the medicament according to any of the above [1] to [1-6] for suppressing a reduction in the total dose of oxaliplatin in the treatment of the antineoplastic tumor.
- the item numbers quoted as in [1] to [1-6] above are shown in a range, and a term having a branch number such as [1-2] is arranged in the range, This means that terms having branch numbers such as [1-2] are also cited. The same applies to the following.
- oxaliplatin is intravenously administered to a human cancer patient once daily for 1 to 3 days at 50 to 150 mg / m 2 (body surface area), and then the drug is stopped for at least 13 days.
- the above-mentioned anti-malignant tumor treatment using oxaliplatin is performed by intravenously administering 50 to 150 mg / m 2 (body surface area) of oxaliplatin once a day for 1 day to a human cancer patient, and then taking a drug suspension for 13 to 24 days
- the above-mentioned antineoplastic treatment with oxaliplatin is performed by intravenously administering 80 to 140 mg / m 2 (body surface area) of oxaliplatin once a day for 1 day to a human cancer patient, and then taking a rest for at least 13 days.
- the above-mentioned anti-malignant tumor treatment with oxaliplatin is performed by intravenously administering 80 to 90 mg / m 2 (body surface area) of oxaliplatin once a day to a human cancer patient for one day and then resting for at least 13 days.
- the above-mentioned antineoplastic treatment with oxaliplatin is performed by intravenously administering 120 to 140 mg / m 2 (body surface area) of oxaliplatin once a day to a human cancer patient for one day, and then taking a rest for at least 20 days.
- [3-7] The medicament according to any of [3] to [3-5], wherein the number of cycles in the anti-malignant tumor treatment is at least eight.
- [3-8] The medicament according to any of the above [3] to [3-5], wherein the number of cycles in the anti-malignant tumor treatment is at least 12 times.
- [4] The medicament according to any of [1] to [3-4], [3-6], or [3-7], wherein oxaliplatin is administered by FOLFOX therapy.
- [5] The medicament according to any of [1] to [4], wherein the thrombomodulin administration is started before the administration of oxaliplatin.
- [5-2] The medicament according to any one of [1] to [4], wherein the thrombomodulin administration is started 30 minutes to 3 hours before the start of oxaliplatin administration.
- [6] The medicament according to any of [1] to [5-2], which is administered to a cancer patient suffering from one or more types of cancer selected from the group consisting of colon cancer, pancreatic cancer, and gastric cancer.
- the thrombomodulin is a soluble thrombomodulin.
- a peptide obtained from a transformed cell prepared by transfecting a DNA encoding the amino acid sequence of any of the following (i-1) or (i-2) into a host cell, , (I-2) a peptide obtained from DNA encoding the amino acid sequence, wherein the peptide has thrombomodulin activity); (I-1) the amino acid sequence of any one of SEQ ID NO: 1 or SEQ ID NO: 3, or (i-2) one or more amino acids of the amino acid sequence of (i-1) above are substituted, deleted, or Added amino acid sequence.
- the thrombomodulin is a peptide obtained from a transformed cell prepared by transfecting a DNA encoding the following amino acid sequence (i-1) into a host cell, [1] to [7]. ] The medicament according to any of [1]; (I-1) the amino acid sequence of any one of SEQ ID NO: 1 and SEQ ID NO: 3; [11] The above-mentioned [1] to [7], wherein the thrombomodulin is a peptide having an amino acid sequence of any of the following (i-1) or (i-2), wherein the peptide has thrombomodulin activity: The medicament according to any of the above, (I-1) the amino acid sequence at positions 19 to 516 in the amino acid sequence of either SEQ ID NO: 1 or SEQ ID NO: 3, or (i-2) one or more of the amino acid sequences of (i-1) An amino acid sequence in which the amino acid has been substituted, deleted or added.
- thrombomodulin is a peptide having the following amino acid sequence (i-1), and the peptide is a peptide having thrombomodulin activity: ; (I-1) an amino acid sequence at positions 19 to 516 in the amino acid sequence of either SEQ ID NO: 1 or SEQ ID NO: 3; [12] The medicament according to any of [1] to [9], wherein the thrombomodulin is thrombomodulin alpha (genetical recombination).
- thrombomodulin for producing a medicament for reducing the symptom and / or suppressing the onset of peripheral neuropathy caused by an antineoplastic agent in a human cancer patient who is treated with an oxaliplatin-based antineoplastic tumor
- the malignant tumor treatment is a treatment in which oxaliplatin is intravenously administered to a human cancer patient and then is stopped for one cycle, and this is repeated as one cycle.
- thrombomodulin 0.06 mg / kg is used.
- [13-2] The use of the above-mentioned [13], which has the features of the above-mentioned [1] to [12].
- thrombomodulin for reducing the symptom and / or suppressing the onset of peripheral neuropathy by an anti-neoplastic agent in a human cancer patient who receives anti-neoplastic treatment with oxaliplatin, wherein the anti-neoplastic treatment comprises oxaliplatin
- This treatment is repeated as one cycle of intravenous administration to a human cancer patient and then withdrawal from the drug, and thrombomodulin 0.06 mg / kg intravenously once per cycle on the first day of each cycle of the antineoplastic treatment.
- a method for reducing symptom and / or suppressing the onset of peripheral neuropathy by an anti-neoplastic agent in a human cancer patient who receives anti-neoplastic treatment with oxaliplatin comprising the step of administering thrombomodulin to a human cancer patient.
- the antineoplastic treatment is a treatment in which oxaliplatin is intravenously administered to a human cancer patient, and thereafter, the treatment is repeated as one cycle, and then each cycle of the antineoplastic treatment is performed.
- the intravenous administration of thrombomodulin 0.06 mg / kg once per cycle on the first day of the procedure.
- FIG. 1 shows the results of investigating the preventive effect of ART-123 7 times administration on hyperalgesia (decrease of pressure-stimulated pain threshold) caused by oxaliplatin administration in rats.
- Oxaliplatin (6 mg / kg) was intraperitoneally administered to all cases at the timing indicated by the white arrow.
- Arrow: ART-123 or vehicle administration ⁇ : vehicle group, ⁇ : ART-123 @ 0.3 mg / kg administration group, ⁇ : ART-123 @ 1 mg / kg administration group, ⁇ : ART-123 @ 10 mg / kg administration group, * *: P ⁇ 0.005 (comparison with vehicle group), ##: p ⁇ 0.01 (comparison with vehicle group on the day before oxaliplatin administration)
- FIG. 1 shows the results of investigating the preventive effect of ART-123 7 times administration on hyperalgesia (decrease of pressure-stimulated pain threshold) caused by oxaliplatin administration in rats.
- Oxaliplatin (6 mg / kg
- examples of the thrombomodulin include a peptide having at least the sequence of positions 19 to 516 of SEQ ID NO: 1 or SEQ ID NO: 3, or a homologous mutant thereof, and having the following thrombomodulin activity.
- a peptide comprising the sequence of positions 19 to 516 of SEQ ID NO: 1 is exemplified.
- a peptide containing the homologous mutant sequence of SEQ ID NO: 1 is exemplified.
- Examples of the homologous mutant sequence include a peptide sequence in which one or more amino acids may be substituted, deleted, or added in the amino acid sequence of the target peptide.
- the number of amino acids which may be substituted, deleted or added is, for example, 1 to 40, preferably 1 to 20, more preferably 1 to 10, further preferably 1 to 5, particularly preferably 1 to 5.
- Preferably 1 to 3 are exemplified.
- Examples of the homologous mutant sequence include a peptide sequence having a certain degree of homology in the amino acid sequence of the target peptide. The homology of a certain degree or more is 80% or more, preferably 85% or more, more preferably 90% or more, still more preferably 95% or more, and particularly preferably 98% or more.
- the thrombomodulin activity include (1) an action of selectively binding to thrombin and (2) an action of promoting the activation of protein C by thrombin.
- thrombomodulin activity examples include those having the above-mentioned actions (1) and (2), and further having the above-mentioned actions (1) to (4). Further, as another aspect, it is exemplified that it has all the effects of (1) to (5).
- the binding action of thrombomodulin to thrombin is known in various types of tests including, for example, tests described in Thrombosis and Haemostasis 1993 70 (3): 418-422 and The Journal of Biological Chemistry 1989 264 (9): 4872-4876.
- the action of promoting the activation of protein C by thrombin may be, for example, the action of promoting the activation of protein C by a test method clearly described in various known documents such as Japanese Patent Application Laid-Open No. 6219/1988.
- the activity amount and the presence or absence thereof can be easily confirmed.
- the effect of prolonging the coagulation time by thrombin and / or the effect of suppressing platelet aggregation by thrombin can be easily confirmed.
- the anti-inflammatory effect can also be confirmed by the test methods described in various publicly known documents including, for example, Blood 2008 112: 3361-3670 and The Journal of Clinical Investigation 2005 115 (5): 1267-1274.
- the thrombomodulin is exemplified by a peptide consisting of the sequence at positions 19 to 516, 19 to 515, 17 to 516, or 17 to 515 in SEQ ID NO: 1 or SEQ ID NO: 3. You. Thrombomodulin may be a mixture of peptides consisting of the sequence at positions 19-516, 19-515, 17-516, or 17-515 in SEQ ID NO: 1 or SEQ ID NO: 3. In one embodiment, the thrombomodulin is not particularly limited as long as it is the thrombomodulin, and examples thereof include soluble thrombomodulin. In another embodiment, human thrombomodulin is exemplified.
- human soluble thrombomodulin is exemplified.
- thrombomodulin alpha (genetical recombination) is exemplified.
- Thrombomodulin alpha (genetical recombination) is an active ingredient of Lycomodulin (registered trademark) which has been approved as a pharmaceutical in Japan.
- Lycomodulin registered trademark
- Thrombomodulin alpha (genetical recombination) is sometimes referred to as ART-123.
- Examples of the soluble thrombomodulin include thrombomodulin that is soluble in water in the absence of a surfactant.
- Preferred examples of the solubility of soluble thrombomodulin include 1 mg / mL with respect to water, for example, distilled water for injection (in the absence of a surfactant such as Triton X-100 or polidocanol, usually near neutrality). Or more, or 10 mg / mL or more, preferably 15 mg / mL or more, or 17 mg / mL or more, more preferably 20 mg / mL or more, 25 mg / mL or more, or 30 mg / mL or more. Preferably, it is 60 mg / mL or more, and in some cases, 80 mg / mL or more, or 100 mg / mL or more.
- the molecular weight of thrombomodulin is preferably 100,000 or less, more preferably 90,000 or less, further preferably 80,000 or less, particularly preferably 70,000 or less, and the lower limit of the molecular weight is 50,000 or less. It is more preferably at least 000, particularly preferably at least 60,000.
- the molecular weight of soluble thrombomodulin can be easily measured by a usual method for measuring the molecular weight of a protein, but is preferably measured by mass spectrometry, and more preferably the MALDI-TOF-MS method.
- a soluble thrombomodulin encoding a soluble thrombomodulin is obtained by culturing a transformed cell prepared by transfecting a host cell with a DNA encoding a soluble thrombomodulin. It can be obtained by fractionating thrombomodulin by column chromatography or the like.
- thrombomodulin can be obtained from a transformed cell prepared by transfecting a DNA encoding these peptides (for example, the nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 4) into a host cell using a vector. .
- these peptides need only have the above-mentioned amino acid sequence, and may or may not have a sugar chain, and this point is not particularly limited.
- the type of sugar chain, the addition position and the degree of addition are different depending on the type of host cell used, and any of them can be used.
- thrombomodulin binds two types of N-linked sugar chains of fucosyl biantennary type and fucosyl triantennary type, and the ratio is exemplified by (100: 0) to (60:40), (95: 5) to (60:40) are preferable, and (90:10) to (70:30) are more preferable examples.
- the ratio of these sugar chains can be measured by a two-dimensional sugar chain map described in Biochemical Experimental Method 23, Glycoprotein Sugar Chain Research Method, Gakkai Shuppan Center (1990) and the like.
- sugar composition of thrombomodulin in one embodiment when the sugar composition of thrombomodulin in one embodiment is examined, neutral sugar, amino sugar, and sialic acid are detected, and a ratio of 1 to 30% by weight is independently exemplified for the protein content, It is preferably from 2 to 20%, more preferably from 5 to 10%.
- sugar contents can be determined by the methods described in Shinsei Kagaku Jikken Koza 3 Glycoprotein I Glycoprotein (above), Tokyo Kagaku Dojin (1990) (neutral sugar: phenol-sulfuric acid method, amino sugar: Elson-Morgan method, sialic acid). : Periodate-resorcinol method).
- a method is preferably employed in which the DNA sequence encoding thrombomodulin is preferably incorporated into a vector, particularly preferably an expression vector that can be expressed in animal cells.
- An expression vector is a DNA molecule comprising a promoter sequence, a sequence for providing a ribosome binding site to mRNA, a DNA sequence encoding a protein to be expressed, a splicing signal, a transcription termination terminator sequence, a replication origin sequence, and the like, and is preferable.
- animal cell expression vectors include pSV2-X reported by Mulligan RC et al.
- Animal cells can be used as host cells that can be used for producing these peptides.
- Animal cells include Chinese hamster ovary (CHO) cells, COS-1 cells, COS-7 cells, VERO (ATCC @ CCL-81) cells, BHK cells, canine kidney-derived MDCK cells, hamster AV-12-664 cells, and the like. And HeLa cells, WI38 cells, human 293 cells, PER. C6 cells.
- CHO cells are very common and preferred, and among CHO cells, dihydrofolate reductase (DHFR) deficient CHO cells are more preferred.
- DHFR dihydrofolate reductase
- microorganisms such as Escherichia coli are often used in the process of gene manipulation and in the process of peptide production, and it is preferable to use a host-vector system suitable for each of them. can do.
- the gene of thrombomodulin used in the gene recombination technique has been cloned, and a production example using the gene recombination technique of thrombomodulin has been disclosed, and further, a purification method for obtaining a purified product thereof is also known.
- thrombomodulin can be produced by using the method described in the above report or according to the method described therein.
- JP-A-64-6219 discloses Escherichia coli K-12 strain DH5 (ATCC Deposit No. 67283) containing plasmid pSV2TMJ2 containing DNA encoding full-length thrombomodulin.
- thrombomodulin in one embodiment can be prepared by a known gene manipulation technique.
- thrombomodulin may be prepared by a conventionally known method or a method analogous thereto.
- the method of Yamamoto et al. [JP-A-64-2219] or JP-A-5-213998 can be used.
- a human-derived thrombomodulin gene can be converted into, for example, a DNA encoding the amino acid sequence of SEQ ID NO: 1 by a genetic engineering technique, and further modified as necessary. This modification includes, for example, a codon encoding the amino acid at position 473 of SEQ ID NO: 1 to obtain a DNA encoding the amino acid sequence of SEQ ID NO: 3 (specifically, consisting of the nucleotide sequence of SEQ ID NO: 4).
- the base at position 1418 of SEQ ID NO: 2 is subjected to site-specific mutation according to the method of Zoller MJ et al. [Methods in Enzymology 1983, 100: 468-500, Academic Press].
- the base T at position 1418 in SEQ ID NO: 2 can be DNA converted to base C using a synthetic DNA for mutation having the base sequence shown in SEQ ID NO: 5.
- the DNA thus prepared is incorporated into, for example, Chinese hamster ovary (CHO) cells to obtain transformed cells, appropriately selected, and thrombomodulin purified by a known method from a culture obtained by culturing the cells. Can be manufactured.
- the DNA encoding the amino acid sequence of SEQ ID NO: 1 (SEQ ID NO: 2) is preferably transfected into the host cell.
- the method for producing thrombomodulin in one embodiment is not limited to the above method, and can be, for example, extracted and purified from urine, blood, other body fluids, etc., or a tissue or a tissue that produces thrombomodulin. Extraction and purification from a tissue culture solution or the like can be performed, and if necessary, further cleavage treatment can be performed with a protease.
- a medium used for ordinary cell culture it is possible to use a medium used for ordinary cell culture, and pre-culture the transformed cells in various media to select an optimal medium.
- a known medium such as a MEM medium, a DMEM medium, or a 199 medium may be used as a basic medium, and a medium to which a supplement for various kinds of medium is added or improved may be used.
- the culture method include serum culture in which the culture is performed in a medium to which serum is added, and serum-free culture in which the culture is performed in a medium to which serum is not added.
- the culture method is not particularly limited, but serum-free culture is preferred.
- bovine serum when serum is added to the medium, bovine serum is preferred.
- the bovine serum includes fetal calf serum, newborn calf serum, calf serum, adult calf serum, and the like, and any suitable serum for cell culture may be used.
- a commercially available medium can be used as the serum-free medium.
- Serum-free media suitable for various cells are commercially available. For example, for CHO cells, CD-CHO, CHO-S-SFMII, and CHO-III-PFM are available from Invitrogen and IS @ CHO are available from Irvine Scientific. And IS @ CHO-CD medium. These media may be used as they are, or may be used after adding or supplementing them.
- examples of the serum-free medium include a DMEM medium to which insulin, transferrin, and selenite are added at a concentration of 5 mg / L.
- the medium is not particularly limited as long as it is a medium that can produce thrombomodulin in one embodiment.
- the culture method is not particularly limited, and may be any culture method such as batch culture, repeated batch culture, fed-batch culture, and perfusion culture.
- the amino acid at position 17, 18, 19, or 22 in SEQ ID NO: 1 may be the N-terminus.
- the N-terminal amino acid may be modified so that glutamic acid at position 22 is converted to pyroglutamic acid.
- the amino acid at position 17 or 19 is N-terminal, and more preferably the amino acid at position 19 is N-terminal.
- soluble thrombomodulin when produced using a DNA having the nucleotide sequence of SEQ ID NO: 2, diversity in the C-terminal amino acid may be observed, and a peptide shorter by one amino acid residue may be produced. That is, the C-terminal amino acid may be modified such that the amino acid at position 515 becomes the C-terminal and the position 515 is amidated. In some cases, peptides shorter by two amino acid residues are produced. That is, the amino acid at position 514 may be the C-terminus. Therefore, a peptide rich in N- and C-terminal amino acids or a mixture thereof may be produced.
- the amino acid at position 515 or the amino acid at position 516 is preferably C-terminal, and more preferably the amino acid at position 516 is C-terminal. In another embodiment, the amino acid at position 514 is preferably C-terminal.
- ⁇ ⁇ ⁇ Thrombomodulin obtained by the above method may be a mixture of peptides having diversity at the N-terminal and C-terminal. Specifically, a peptide consisting of the sequence at positions 19 to 516, 19 to 515, 19 to 514, 17 to 516, 17 to 515, or 17 to 514 in SEQ ID NO: 1 Mixtures are mentioned.
- the method of isolating and purifying thrombomodulin from the culture supernatant or culture obtained as described above can be performed according to a known method [Edited by Takeichi Horio, Basic Experimental Methods for Proteins and Enzymes, 1981].
- a known method Edited by Takeichi Horio, Basic Experimental Methods for Proteins and Enzymes, 1981.
- affinity chromatography utilizing specific affinity for thrombomodulin is also a preferred example.
- Preferred examples of the adsorbent include an example using an antibody to thrombin or thrombomodulin, which is a ligand of thrombomodulin.
- thrombomodulin antibody that recognizes an appropriate property or an appropriate epitope can be used.
- hydrophobic chromatography utilizing a hydrophobic bond between a chromatography carrier having a hydrophobic group immobilized thereon and a hydrophobic site of thrombomodulin can be mentioned.
- hydroxyapatite can be used as a carrier for the adsorption chromatography, and examples thereof include the examples described in JP-A-9-110900. These techniques can be appropriately combined.
- the degree of purification can be selected depending on the purpose of use. For example, the results of electrophoresis, preferably SDS-PAGE, are obtained as a single band, or the results of gel filtration HPLC or reverse phase HPLC of isolated purified products are obtained as a single band. It is desirable to purify to one peak.
- the band be substantially only thrombomodulin, and it is not required that the band be a single band.
- a specific example of the method of purifying thrombomodulin in one embodiment is a method of purifying thrombomodulin using an index of thrombomodulin activity.
- a culture supernatant or culture is roughly purified using Q-Sepharose Fast @ Flow of an ion exchange column.
- a fraction having thrombomodulin activity was collected, and then a main purification was performed using a DIP-thrombin-agarose (diisopropylphosphorylthrombin agarose) column of an affinity column, a fraction having strong thrombomodulin activity was collected, and the collected fraction was concentrated and subjected to gel filtration.
- DIP-thrombin-agarose diisopropylphosphorylthrombin agarose
- a purification method for obtaining a fraction as a pure product [Gomi K et al, Blood 1990; 75: 1396-1399] may be mentioned.
- the thrombomodulin activity used as an indicator includes, for example, the activity of promoting the activation of protein C by thrombin.
- Other preferred purification methods are as follows.
- a particularly preferred example is a method using Q-Sepharose Fast @ Flow equilibrated with a 0.02 mol / L Tris-HCl buffer (pH 7.4) containing 0.18 mol / L @NaCl. After appropriate washing, elution is performed with, for example, 0.02 mol / L Tris-HCl buffer (pH 7.4) containing 0.3 mol / L NaCl to obtain thrombomodulin as a crude product.
- a substance having a specific affinity for thrombomodulin can be immobilized on a resin and affinity chromatography purified.
- Preferred examples include a DIP-thrombin-agarose column and an anti-thrombomodulin monoclonal antibody column.
- the DIP-thrombin-agarose column is preliminarily equilibrated with, for example, a 20 mmol / L Tris-HCl buffer (pH 7.4) containing 100 mmol / L NaCl and 0.5 mmol / L calcium chloride, and charged with the above crude product.
- thrombomodulin as a purified product.
- 20 mmol / L Tris-HCl buffer pH 7.4 containing 1.0 mol / L NaCl and 0.5 mmol / L calcium chloride to obtain thrombomodulin as a purified product.
- a 0.5 mol / L NaCl-containing 0.1 mol / L NaHCO3 buffer solution in which an anti-thrombomodulin monoclonal antibody was dissolved in Sepharose 4FF (GE Healthcare Bioscience) previously activated with CNBr was used.
- a column packed with a resin in which Sepharose 4FF was coupled with an anti-thrombomodulin monoclonal antibody was previously filled with, for example, a 20 mmol / L phosphate buffer (pH 7.3) containing 0.3 mol / L NaCl.
- a method of eluting with a 100 mmol / L glycine hydrochloride buffer (pH 3.0) containing 0.3 mol / L @NaCl is exemplified.
- the eluate can be neutralized with an appropriate buffer and obtained as a purified product.
- the purified product obtained is adjusted to pH 3.5, and then a cation exchanger, preferably a strong cation, equilibrated with a 100 mmol / L glycine hydrochloride buffer (pH 3.5) containing 0.3 mol / L NaCl.
- a cation exchanger preferably a strong cation
- the SP-Sepharose FF which is an exchanger, is charged and washed with the same buffer to obtain a non-adsorbed fraction.
- the obtained fraction is neutralized with an appropriate buffer and can be obtained as a highly purified product. These are preferably concentrated by ultrafiltration.
- buffer exchange by gel filtration.
- a high-purity purified product concentrated by ultrafiltration is charged on a Sephacryl @ S-300 or S-200 column equilibrated with a 20 mmol / L phosphate buffer (pH 7.3) containing 50 mmol / L @NaCl. Then, the fraction is developed and fractionated with a 20 mmol / L phosphate buffer (pH 7.3) containing 50 mmol / L NaCl, and the activity of accelerating the activation of protein C by thrombin is confirmed to collect the active fraction.
- the exchanged high-purity purified product can be obtained.
- the high-purity purified product thus obtained is preferably filtered using a suitable virus-removing membrane, for example, Planova 15N (Asahi Kasei Medical Co., Ltd.), in order to enhance safety. Can be concentrated. Finally, it is preferable to filter through a sterile filtration membrane.
- a suitable virus-removing membrane for example, Planova 15N (Asahi Kasei Medical Co., Ltd.)
- the “peripheral neuropathy caused by an anti-neoplastic agent” is exemplified by a peripheral neuropathy caused by administering an anti-neoplastic agent as exemplified above to a human cancer patient. In the present specification, it may be referred to as "chemotherapy-induced peripheral neuropathy”.
- the “anti-neoplastic agent” is exemplified by an agent that exhibits some clinical usefulness in a patient with a malignant tumor, such as suppression of an increase or metastasis of a malignant tumor, prolongation of life, and control of symptoms.
- oxaliplatin is exemplified.
- the peripheral neuropathy due to the antineoplastic agent is exemplified by peripheral neuropathy due to oxaliplatin.
- Oxaliplatin is an antineoplastic agent that inhibits the metabolism of nucleic acids and is classified as a platinum preparation. Oxaliplatin is an active ingredient of Elplat (registered trademark) which has been approved as a pharmaceutical in Japan. Peripheral neuropathy due to antineoplastic agents in human cancer patients undergoing antineoplastic treatment with oxaliplatin is sometimes referred to as oxaliplatin-induced peripheral neuropathy.
- peripheral neuropathy includes numbness of the extremities, pain in the extremities, decreased deep tendon reflexes, decreased muscle strength, allodynia (sometimes called "allodynia”), hyperalgesia and motor dysfunction.
- Other peripheral nerve disorders include distress such as stinging and burning pain, numbness in the extremities of the extremities, abnormal perception such as burning sensation, hypersensitivity such as hypersensitivity to cold sensation, loss of sensation, sensation of sensation and discomfort. Dysesthesia, sensory ataxia, and decreased muscle strength.
- Peripheral neuropathy can be broadly classified into three types: peripheral motor neuropathy, peripheral sensory neuropathy, or peripheral autonomic neuropathy, but is not limited thereto. Examples of peripheral motor neuropathy include inflammation or degeneration of peripheral motor nerves, examples of peripheral sensory neuropathy include inflammation or degeneration of peripheral sensory nerves, and examples of peripheral autonomic neuropathy include inflammation or degeneration of peripheral autonomic nerves.
- NCI-CTCAE Common Terms for Adverse Events v4.0 Japanese translation JCOG version
- NCI-CTCAE the physician can confirm the effect on peripheral motor neuropathy or sensory neuropathy, and on FACT / GOG-NTX-12, the patient can confirm the effect on oxaliplatin-induced peripheral neuropathy. be able to.
- peripheral motor neuropathy or sensory neuropathy is not present, and Grade 1 (no symptoms), Grade 2 (moderate symptoms), Grade 3 (high symptoms), Grade 4 (life Threatening) and Grade 5 (death).
- the human cancer patient is not particularly limited as long as it is a human cancer patient requiring treatment with oxaliplatin, and is exemplified by a human cancer patient suffering from colorectal cancer, pancreatic cancer, or gastric cancer.
- a human cancer patient suffering from colorectal cancer or gastric cancer is exemplified.
- colorectal cancer is exemplified. Examples of colorectal cancer include rectal cancer and colon cancer.
- thrombomodulin can also be used in adjuvant chemotherapy for the purpose of suppressing postoperative recurrence. Furthermore, it can be administered to human cancer patients with recurrent or metastatic cancer.
- a cycle in the treatment with an anti-neoplastic agent is a unit of treatment with the anti-neoplastic agent that combines a period of treatment with the anti-neoplastic agent and a period of rest.
- the day on which the administration of the antineoplastic agent (oxaliplatin) is started is defined as the first day of one cycle.
- oxaliplatin when oxaliplatin is intravenously administered to a human cancer patient and then withdrawal is repeated as one cycle, the oxaliplatin is administered to a human cancer patient at 1 to 10 times.
- An example is a treatment in which administration is performed six times intravenously, and thereafter, the treatment is repeated for one cycle of taking at least 6 days of drug holiday.
- Oxaliplatin can be used, for example, according to the usage described in the Elplat (registered trademark) package insert or the Eloxatin label.
- the number of times oxaliplatin is administered in one cycle of an oxaliplatin-based antineoplastic treatment is, for example, 1 to 6 times, 1 to 3 times as another embodiment, and 1 time as another embodiment. Is exemplified.
- administration once every two weeks is exemplified, and as another embodiment, administration once a week is exemplified.
- daily administration is exemplified.
- the antineoplastic agent is administered once a day.
- the period during which the antineoplastic agent (oxaliplatin) is withdrawn is, for example, at least 6 days, as another embodiment, at least 13 days, and as another embodiment, At least 20 days are illustrated. Yet another embodiment is exemplified from 6 days to 24 days, still another embodiment is exemplified from 13 days to 24 days, still another embodiment is exemplified from 13 days to 20 days, and still another embodiment is 13 days. Another example is 20 days.
- the suspension period of oxaliplatin may be set to 3 to 6 weeks for a certain period of time, which is also one embodiment.
- the number of cycles when one cycle is repeated is, for example, 1 to 24 times, 1 to 18 times in another embodiment, and 1 to 18 in another embodiment. Twelve times are exemplified. Still another embodiment is exemplified by 1 to 6 times. Still another embodiment is exemplified at least six times. Yet another example is at least eight times. Yet another example is at least 12 times. Yet another example is at least 18 times. Still another embodiment is exemplified at least 24 times.
- the dose of oxaliplatin per dose is, for example, 50 to 150 mg / m 2 per body surface area of a human cancer patient, 80 to 140 mg / m 2 as another embodiment, and 80 to 90 mg / m 2 as another embodiment.
- / M 2 90 to 110 mg / m 2 as another embodiment, 120 to 140 mg / m 2 as another embodiment, and 85 mg / m 2 as another embodiment,
- 100 mg / m 2 is exemplified
- 130 mg / m 2 is exemplified.
- the body surface area of a human cancer patient can be determined from the height and weight of the human cancer patient.
- the method of calculating the body surface area can be appropriately calculated in light of the common technical knowledge. For example, it can be calculated by the following DuBois formula (Dubois D and Dubois EF: Arch Intern Med, 17, 863-871, 1916). .
- Body surface area (m 2) height (cm) 0.725 ⁇ Weight (kg) 0.425 ⁇ 0.007184
- the rate of intravenous administration of oxaliplatin is not particularly limited as long as it is a commonly used infusion rate, and it is exemplified that the required amount of oxaliplatin is administered within 3 hours. The administration is exemplified.
- (a) to (f) are exemplified as anti-malignant tumor treatment with oxaliplatin.
- A Administer 80 to 90 mg / m 2 (body surface area) of oxaliplatin intravenously once a day to human cancer patients, and suspend the drug for at least 13 days. The administration is repeated as one cycle.
- B 85 mg / m 2 (body surface area) of oxaliplatin is intravenously administered to human cancer patients once a day, and the drug is rested for at least 13 days. The administration is repeated as one cycle.
- oxaliplatin can be administered in combination with multiple antineoplastic agents having different mechanisms of action.
- oxaliplatin can be administered by FOLFOX therapy.
- FOLFOX therapy is an antineoplastic treatment that combines oxaliplatin with fluorouracil and levofolinate.
- FOLFOX therapy is classified into, for example, FOLFOX2, FOLFOX3, FOLFOX4, FOLFOX6, mFOLFOX6, FOLFOX7, or mFOLFOX7 according to the method of administration.
- Oxaliplatin can be administered by XELOX therapy (CapOX therapy), FOLFOXIRI therapy, FOLFIRINOX therapy, or SOX therapy.
- XELOX therapy is an antineoplastic treatment that combines oxaliplatin with capecitabine.
- FOLFOXIRI or FOLFIRINOX therapy is an antineoplastic treatment that combines oxaliplatin with irinotecan hydrochloride hydrate, fluorouracil, and levoforinate.
- SOX therapy is an antineoplastic treatment in which oxaliplatin is combined with S-1 (a combination of potassium tegafur, gimeracil, and oteracil).
- antineoplastic agent to be administered in combination with oxaliplatin examples include fluorouracil, capecitabine, a combination of tegafur, gimeracil, and oteracil potassium, irinotecan, bevacizumab, cetuximab, panitumumab, or trastuzumab. Also, in one embodiment, oxaliplatin can be administered with an antiemetic or antiallergic agent.
- thrombomodulin can be administered intravenously on the first day of each cycle of the antineoplastic agent. In addition, thrombomodulin can be administered once per cycle. In one embodiment, the thrombomodulin can be administered prior to beginning administration of the antineoplastic agent. It can also be administered after the start of the administration of the antineoplastic agent. In addition, administration of thrombomodulin and antineoplastic agent can be started simultaneously.
- the number of hours before administration of the antineoplastic agent to administer thrombomodulin is determined by the effect of the antineoplastic agent on the reduction and / or suppression of peripheral neuropathy.
- an example is 9 days or more before the start of administration of the antineoplastic agent
- another example is 7 days or later before the start of administration of the antineoplastic agent
- another embodiment is an anti-malignant tumor 5 days or more before the start of the administration of the antineoplastic agent
- another example is 12 hours or more before the start of the administration of the antineoplastic agent.
- the number of hours after the start of the administration of the antineoplastic agent, how long the thrombomodulin is administered is to reduce the effect of the antineoplastic agent on the symptom reduction and / or suppress the onset of peripheral neuropathy.
- the medicament of the present invention may contain a carrier.
- a carrier that can be used in the present invention, a water-soluble carrier is preferable, and for example, it can be prepared by adding sucrose, glycerin, or the like, or a pH adjuster of other inorganic salts as an additive. If necessary, amino acids, salts, carbohydrates, surfactants, albumin, gelatin, etc. may be added, as disclosed in JP-A-1-6219 and JP-A-6-321805. It is also preferable to add a preservative, for example, a parabenzoic acid ester is a preferred example, and methyl parabenzoate is a particularly preferred example.
- the amount of the preservative to be added is usually 0.01 to 1.0% (indicating weight%, the same applies hereinafter), and preferably 0.1 to 0.3%. These addition methods are not particularly limited.
- freeze-drying as is usually performed, for example, a method of mixing a solution containing an antineoplastic agent and a thrombomodulin-containing solution, and then adding and mixing the additives.
- a solution is prepared by adding and mixing a thrombomodulin-containing solution, and then lyophilized.
- the medicament of the present invention may be provided in the form of an injection solution, or may be provided in a form in which a lyophilized preparation is dissolved and used at the time of use.
- a solution containing 0.05 to 15 mg, preferably 0.1 to 5 mg, of thrombomodulin per 1 mL of water, distilled water for injection, or an appropriate buffer and the above additive is added to an ampoule or a vial.
- a method of filling after filling with 0.5 to 10 mL, freezing, and drying under reduced pressure is exemplified.
- it can be prepared as it is as an aqueous injection preparation.
- the administration method of the medicament of the present invention is not particularly limited as long as it can exert the effect of reducing and / or suppressing the onset of peripheral neuropathy caused by the antineoplastic agent.
- Intravenous administration is exemplified.
- a method of administering a desired amount at a time or intravenous drip infusion may be mentioned.
- the method of administering a desired amount at one time is preferable in that the administration time is short.
- the time required for administration with a syringe generally has a range, but the time required for administration depends on the amount of liquid to be administered, and is, for example, 5 minutes or less, preferably 3 minutes or less. 2 minutes or less, more preferably 1 minute or less, particularly preferably 30 seconds or less.
- the lower limit is not particularly limited, but is preferably 1 second or longer, more preferably 5 seconds or longer, and even more preferably 10 seconds or longer.
- the dose is not particularly limited as long as it is the above preferred dose. Intravenous drip infusion is preferable because it is easy to keep the blood concentration of thrombomodulin constant.
- the daily dose of thrombomodulin varies depending on the age, weight, degree of disease, administration route, etc. of the patient, but is exemplified by 0.06 mg / kg.
- the medicament of the present invention exerts an effect of alleviating symptoms and / or suppressing the onset of peripheral neuropathy caused by an anti-neoplastic agent.
- Symptom reduction refers to symptoms that usually occur when oxaliplatin is administered, such as sensory numbness of hands and feet, tingling pain and discomfort, and pain in the hands or feet when exposed to low temperatures. It is mild. Suppression of onset means that peripheral nervous disorders usually occurring when oxaliplatin is administered, such as peripheral motor neuropathy or peripheral sensory neuropathy, are suppressed to a certain level or less (for example, Grade 1 or less in NCI-CTCAE).
- Hand or foot pain can be evaluated by Numerical Rating Scale (hereinafter sometimes abbreviated as NRS). In the NRS, the pain intensity can be evaluated on an 11-point scale, with 0 indicating no pain at all and 10 as the worst possible pain.
- NRS Numerical Rating Scale
- the medicament of the present invention comprises the sum of oxaliplatin doses of all cycles to be normally administered in human cancer patients when one to multiple cycles of anti-malignant tumor treatment with oxaliplatin are performed.
- the total dose of oxaliplatin to be administered is reduced as compared with the total dose (A).
- the total dose of oxaliplatin in one to multiple cycles in the treatment of an anti-malignant tumor with oxaliplatin when the medicament of the present invention is administered is defined as (B)
- the difference between A and B is A and C
- the ratio of B to A with respect to the average value of the total dose is at least 70%, and in another embodiment, at least 80% In another embodiment, at least 85% is exemplified, as still another embodiment, at least 90% is exemplified, and as still another embodiment, at least 95% is exemplified.
- the ratio of B to C with respect to the average value of the total dose is at least 101%. In another embodiment, it is at least 103%, in another embodiment, it is at least 103%, in another embodiment, it is at least 104%, and in another embodiment, it is at least 105%. In another embodiment, the ratio is at least 110%, in another embodiment, at least 115%, and in still another embodiment, the ratio is at least 120%.
- the medicament of the present invention can be used as a safe medicament with few side effects.
- the medicament of the present invention is selected from other drugs used as a method for treating peripheral neuropathy caused by antineoplastic agents, for example, Chinese medicine, steroids, antidepressants, antiepileptics, opioids and the like.
- drugs used as a method for treating peripheral neuropathy caused by antineoplastic agents, for example, Chinese medicine, steroids, antidepressants, antiepileptics, opioids and the like.
- One or a plurality of drugs can be selected and prepared and administered in combination or as a mixture. It is also possible to administer thrombomodulin in combination with physiotherapy, complementary therapies such as massage and acupuncture.
- SEQ ID NO: 1 amino acid sequence encoded by the gene used to produce ART-123
- SEQ ID NO: 2 nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1
- SEQ ID NO: 3 amino acid encoded by the gene used to produce ART-123M
- SEQ ID NO: 4 Nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3
- SEQ ID NO: 5 Synthetic DNA for mutation used when performing site-specific mutation
- the thrombomodulin of the present invention used in Examples and Comparative Examples was produced according to the method of Yamamoto et al. (Method described in JP-A-64-6219). The production example is shown below.
- the thrombomodulin obtained in this production example is safe in single and repeated intravenous administration tests using rats and monkeys, mouse reproductive tests, local irritation tests, safety pharmacology tests, virus inactivation tests, etc. Has been confirmed.
- freeze-drying was performed under the following conditions in the order of freeze-drying ⁇ filling with nitrogen ⁇ plugging the whole rubber stopper ⁇ tightening the cap to obtain an ART-123-containing preparation containing 2 mg of soluble thrombomodulin and 40 mg of arginine hydrochloride in one container. .
- DNA encoding the amino acid sequence of SEQ ID NO: 3 (specifically, consisting of the nucleotide sequence of SEQ ID NO: 4) was transfected into Chinese hamster ovary (CHO) cells, and the above-described culture solution of the transformed cells was used.
- a thrombomodulin (hereinafter sometimes abbreviated to ART-123M) solution purified by a conventional purification method is obtained, and a freeze-dried preparation of ART-123M is obtained by the same method as described above.
- Example 1 Effect of once administration of ART-123 once per cycle on oxaliplatin-induced peripheral neuropathy in human cancer patients ⁇ Test method> Efficacy and safety of ART-123 for oxaliplatin-induced peripheral neuropathy in patients with pathological stage II or III colon cancer treated with adjuvant chemotherapy including oxaliplatin after radical resection (R0 surgery)
- a placebo control study was performed to examine Postoperative adjuvant chemotherapy with oxaliplatin is mFOLFOX6 (85 mg / m 2 (body surface area) as oxaliplatin administered intravenously once a day for 2 hours, followed by at least 13 days off. The administration was repeated for 12 cycles.
- Subjects were randomly assigned to placebo, ART-123 single dose group, and ART-123 triple dose group.
- placebo was administered on days 1, 2, and 3 of each cycle.
- ART-123 single dose group ART-123 0.06 mg / kg on day 1 of each cycle, and on day 2
- placebo was administered
- 0.06 mg / kg of ART-123 was administered on days 1, 2, and 3 of each cycle.
- ART-123 or placebo was started at the same time as possible on day 1, and intravenous drip was administered for 30 minutes.
- Peripheral neuropathy symptom-reducing effects Table 1 shows the change in the mean-square mean of each group of FACT / GOG-NTX-12 administered from the start of study drug administration to the completion of the study, and the placebo group and ART-123 single administration group. The difference from the three-time administration group was shown. 48 points-The patient rating was scored. The ART-123 group scored higher than the placebo group at 12 cycles, and ART-123 reduced the symptoms of peripheral neuropathy. In addition, the once-administered group of ART-123 was more effective in reducing the symptoms of peripheral neuropathy than the three-administered group of ART-123. Evaluation of hand and foot pain by NRS showed that the once-administered group of ART-123 had a greater analgesic effect than the three-administered group of ART-123.
- Table 2 shows the cumulative expression rate of Grade 2 or higher by NCI-CTCAE (peripheral sensory neuropathy) treatment group evaluated from the start of study drug administration to the completion of the study (up to each cycle) Percentage of patients who developed Grade 2 or more at least once) and the difference between the placebo group and the ART-123 single-dose group or triple-dose group.
- ART-123 at 12 cycles had a lower Grade 2 or higher cumulative expression rate than the placebo group, and ART-123 suppressed the development of peripheral neuropathy.
- the once-administered group of ART-123 was more effective in suppressing the onset of peripheral neuropathy than the three-administered group of ART-123.
- Table 4 shows the cumulative dose of the total dose of oxaliplatin from the start of study drug administration to the completion of the study by administration group. In both the mean and median, the cumulative doses of oxaliplatin were higher in the ART-123 single-dose and triple-dose groups than in the placebo group.
- Safety Table 5 summarizes the number and incidence of adverse events that occurred from the start of study drug administration to the completion of the study for each treatment group by presence / absence of the study drug, severity, and bleeding-related adverse events. And the difference between the placebo group and the ART-123 single dose group or triple dose group. There was no significant difference in the incidence of adverse events between ART-123 single-dose and triple-dose groups compared to placebo, regardless of whether they were related to the study drug, whether they were related to severity, or to bleeding. It was not recognized, and it was confirmed that it can be safely administered.
- ART-123 To examine the preventive effect of ART-123 on oxaliplatin-induced peripheral neuropathy, to examine the number of doses of ART-123 in one cycle of oxaliplatin treatment, rat oxaliplatin-induced peripheral nerve induced by a single administration of an anti-neoplastic agent A failure model evaluation system was constructed.
- ART-123 Dose Between Human and Rat Models
- the pharmacokinetic parameters of rat intravenous administration are as follows: ART-123 at a dose of 0.25 mg / kg, initial plasma concentration (C 0 ) Is 6.14 ⁇ g / mL and the half-life (t 1 / 2 ⁇ ) is 7.2 hours (Licomodulin® application summary section 2.6.4.3.1.1).
- the maximum plasma concentration of ART-123 when intravenously administered at a dose of 0.06 mg / kg of ART-123 is 0.9 to 1.7 ⁇ g / mL (Licomodulin (registered trademark) application summary 2.5.3.2 .1), and has a half-life of about 20 hours (Ricomodulin (registered trademark) application summary section 2.5.3.3).
- Licomodulin registered trademark
- Ricomodulin registered trademark
- ART-123 was administered intraperitoneally to 7-8 week old male Sprague Dawley rats at a dose of 1 mg / kg, and plasma was obtained over time. Plasma concentrations were measured by ELISA and pharmacokinetic parameters were analyzed with a non-compartmental model.
- the half-life of 1 mg / kg intraperitoneal administration of ART-123 in rats is 14.1 hours and, taking into account the tmax of 6 hours, the intraperitoneal administration of rats to human veins with a half-life of about 20 hours. It was thought that it was possible to achieve a plasma concentration transition close to that of internal administration.
- the C max of 1 mg / kg i.p. of ART-123 in rats: 5.47 ⁇ g / mL is the highest plasma concentration of 0.06 mg / kg i.v. of ART-123 in humans (0. (9 to 1.7 ⁇ g / mL), which is about 3 to 6 times, so that intravenous administration of 0.06 mg / kg in humans is close to intraperitoneal administration of about 0.15 to 0.3 mg / kg in rats. It was considered.
- the administration dose at that time was 0.3 mg / kg, 1 mg / kg, or 10 mg / kg (0.3 mg / kg, 1 mg / kg, or 10 mg / kg group, respectively).
- the vehicle was intraperitoneally administered once a day for 7 days (vehicle group).
- a paired t-test was performed at 5% on both sides of the significance level for the pressure stimulation withdrawal threshold of the vehicle group one day before oxaliplatin administration and on day 14 or 21 after oxaliplatin administration (## in FIG. 1). : P ⁇ 0.01).
- FIG. 1 shows the results of prophylactic administration of ART-123 to rats once a day from the day of oxaliplatin administration for 7 days.
- the pressure stimulation withdrawal threshold was significantly reduced as compared to the day before the administration of oxaliplatin, and hyperalgesia had developed.
- the decrease in the pressure stimulation escape threshold observed in the vehicle group was dose-dependently and significantly suppressed from 0.3 mg / kg.
- ART-123 As a single administration group, rats administered with oxaliplatin were intraperitoneally administered with ART-123 once on the day of oxaliplatin administration and once on the next day and the next day, respectively. .
- ART-123 As a twice-administered group, rats administered with oxaliplatin were intraperitoneally administered once with ART-123 once each on the day of oxaliplatin administration and the next day, and once each day on the day after.
- ART-123 As a three-time administration group, ART-123 was intraperitoneally administered once to the rats to which oxaliplatin was administered, on the day of oxaliplatin administration, the next day, and the day after the next day. The dose of ART-123 was 1 mg / kg.
- the vehicle was intraperitoneally administered once a day for 3 days (vehicle group).
- a paired t-test was performed at 5% on both sides of the significance level for the pressure stimulation withdrawal threshold of the vehicle group 1 day before oxaliplatin administration and 14 days or 21 days after oxaliplatin administration (## in FIG. 2). : P ⁇ 0.01).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
〔1〕オキサリプラチンによる抗悪性腫瘍治療を受けるヒト癌患者における抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬であって、前記抗悪性腫瘍治療は、オキサリプラチンをヒト癌患者に静脈内投与し、その後休薬することを1サイクルとしてこれを繰り返す治療であり、前記抗悪性腫瘍治療の各サイクルの初日にトロンボモジュリン0.06mg/kgを1サイクルあたり1回静脈内投与するための、トロンボモジュリンを有効成分として含有する該医薬。
〔1-2〕オキサリプラチンによる抗悪性腫瘍治療を受けるヒト癌患者における抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬であって、前記抗悪性腫瘍治療は、オキサリプラチンをヒト癌患者に1~6回静脈内投与し、その後少なくとも6日間休薬することを1サイクルとしてこれを繰り返す治療であり、前記抗悪性腫瘍治療の各サイクルの初日にトロンボモジュリン0.06mg/kgを1サイクルあたり1回静脈内投与するための、トロンボモジュリンを有効成分として含有する前記〔1〕に記載の医薬。
〔1-3〕前記抗悪性腫瘍治療におけるサイクルの回数が1~12回である前記〔1〕に記載の医薬。
〔1-4〕前記抗悪性腫瘍治療におけるサイクルの回数が少なくとも8回である前記〔1〕又は〔1-2〕に記載の医薬。
〔1-5〕前記抗悪性腫瘍治療におけるサイクルの回数が少なくとも12回である前記〔1〕又は〔1-2〕に記載の医薬。
〔1-6〕オキサリプラチンをヒト癌患者に静脈内投与し、その後休薬することを1サイクルとしてこれを繰り返す治療において、オキサリプラチンによる末梢神経障害の症状軽減及び/又は発症抑制のための医薬であって、治療の各サイクルの初日にトロンボモジュリン0.06mg/kgを1サイクルあたり1回静脈内投与するためのトロンボモジュリンを有効成分として含有する該医薬。
〔2〕前記抗悪性腫瘍治療におけるオキサリプラチン総投与量の低減を抑制するための前記〔1〕~〔1-6〕のいずれかに記載の医薬。
なお、上記〔1〕~〔1-6〕のように引用する項番号が範囲で示され、その範囲内に〔1-2〕等の枝番号を有する項が配置されている場合には、〔1-2〕等の枝番号を有する項も引用されることを意味する。以下においても同様である。
〔3〕前記オキサリプラチンによる抗悪性腫瘍治療が、オキサリプラチン50~150mg/m2(体表面積)を1日1回1~3日間ヒト癌患者に静脈内投与し、その後少なくとも13日間休薬することを1サイクルとしてこれを繰り返す治療である前記〔1〕又は〔2〕に記載の医薬。
〔3-2〕前記オキサリプラチンによる抗悪性腫瘍治療が、オキサリプラチン50~150mg/m2(体表面積)を1日1回1日間ヒト癌患者に静脈内投与し、その後13~24日間休薬することを1サイクルとしてこれを繰り返す治療である前記〔1〕又は〔2〕に記載の医薬。
〔3-3〕前記オキサリプラチンによる抗悪性腫瘍治療が、オキサリプラチン80~140mg/m2(体表面積)を1日1回1日間ヒト癌患者に静脈内投与し、その後少なくとも13日間休薬することを1サイクルとしてこれを繰り返す治療である前記〔1〕又は〔2〕に記載の医薬。
〔3-4〕前記オキサリプラチンによる抗悪性腫瘍治療が、オキサリプラチン80~90mg/m2(体表面積)を1日1回1日間ヒト癌患者に静脈内投与し、その後少なくとも13日間休薬することを1サイクルとしてこれを繰り返す治療である前記〔1〕又は〔2〕に記載の医薬。
〔3-5〕前記オキサリプラチンによる抗悪性腫瘍治療が、オキサリプラチン120~140mg/m2(体表面積)を1日1回1日間ヒト癌患者に静脈内投与し、その後少なくとも20日間休薬することを1サイクルとしてこれを繰り返す治療である前記〔1〕又は〔2〕に記載の医薬。
〔3-6〕前記抗悪性腫瘍治療におけるサイクルの回数が1~12回である前記〔3〕~〔3-5〕のいずれかに記載の医薬。
〔3-7〕前記抗悪性腫瘍治療におけるサイクルの回数が少なくとも8回である前記〔3〕~〔3-5〕のいずれかに記載の医薬。
〔3-8〕前記抗悪性腫瘍治療におけるサイクルの回数が少なくとも12回である前記〔3〕~〔3-5〕のいずれかに記載の医薬。
〔4〕オキサリプラチンがFOLFOX療法により投与される前記〔1〕~〔3-4〕、〔3-6〕、又は〔3-7〕のいずれかに記載の医薬。
〔5〕オキサリプラチンの投与開始前に前記トロンボモジュリン投与が開始される、前記〔1〕~〔4〕のいずれかに記載の医薬。
〔5-2〕オキサリプラチンの投与開始の30分~3時間前に前記トロンボモジュリン投与が開始される、前記〔1〕~〔4〕のいずれかに記載の医薬。
〔6〕大腸癌、膵癌、及び胃癌からなる群より選択される1種以上の癌を患った癌患者に投与される前記〔1〕~〔5-2〕のいずれかに記載の医薬。
〔7〕末梢神経障害が、末梢性運動神経障害又は末梢性感覚神経障害である前記〔1〕~〔6〕のいずれかに記載の医薬。
〔8〕前記トロンボモジュリンが可溶性トロンボモジュリンである前記〔1〕~〔7〕のいずれかに記載の医薬。
〔9〕前記トロンボモジュリンがヒトトロンボモジュリンである前記〔1〕~〔7〕のいずれかに記載の医薬。
〔10〕前記トロンボモジュリンが、下記(i-1)又は(i-2)のいずれかのアミノ酸配列をコードするDNAを宿主細胞にトランスフェクトして調製された形質転換細胞より取得されるペプチド(但し、(i-2)のアミノ酸配列をコードするDNAより取得されるペプチドである場合、該ペプチドはトロンボモジュリン活性を有する)である前記〔1〕~〔7〕のいずれかに記載の医薬;
(i-1)配列番号1又は配列番号3のいずれかに記載のアミノ酸配列、又は
(i-2)上記(i-1)のアミノ酸配列の1つ又は複数のアミノ酸が置換、欠失、又は付加されたアミノ酸配列。
〔10-2〕前記トロンボモジュリンが、下記(i-1)のアミノ酸配列をコードするDNAを宿主細胞にトランスフェクトして調製された形質転換細胞より取得されるペプチドである前記〔1〕~〔7〕のいずれかに記載の医薬;
(i-1)配列番号1又は配列番号3のいずれかに記載のアミノ酸配列。
〔11〕前記トロンボモジュリンが、下記(i-1)又は(i-2)のいずれかのアミノ酸配列を含むペプチドであって、該ペプチドがトロンボモジュリン活性を有するペプチドである前記〔1〕~〔7〕のいずれかに記載の医薬;
(i-1)配列番号1又は配列番号3のいずれかに記載のアミノ酸配列における第19~516位のアミノ酸配列、又は
(i-2)上記(i-1)のアミノ酸配列の1つ又は複数のアミノ酸が置換、欠失、又は付加されたアミノ酸配列。
〔11-2〕前記トロンボモジュリンが、下記(i-1)のアミノ酸配列を含むペプチドであって、該ペプチドがトロンボモジュリン活性を有するペプチドである前記〔1〕~〔7〕のいずれかに記載の医薬;
(i-1)配列番号1又は配列番号3のいずれかに記載のアミノ酸配列における第19~516位のアミノ酸配列。
〔12〕前記トロンボモジュリンがトロンボモデュリン アルファ(遺伝子組換え)である前記〔1〕~〔9〕のいずれかに記載の医薬。
〔13〕オキサリプラチンによる抗悪性腫瘍治療を受けるヒト癌患者における抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬を製造するためのトロンボモジュリンの使用であって、前記抗悪性腫瘍治療は、オキサリプラチンをヒト癌患者に静脈内投与し、その後休薬することを1サイクルとしてこれを繰り返す治療であり、前記抗悪性腫瘍治療の各サイクルの初日にトロンボモジュリン0.06mg/kgを1サイクルあたり1回静脈内投与するための、該使用。
〔13-2〕上記〔1〕~〔12〕に記載の特徴を有する上記〔13〕に記載の使用。
〔14〕オキサリプラチンによる抗悪性腫瘍治療を受けるヒト癌患者における抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のためのトロンボモジュリンであって、前記抗悪性腫瘍治療は、オキサリプラチンをヒト癌患者に静脈内投与し、その後休薬することを1サイクルとしてこれを繰り返す治療であり、前記抗悪性腫瘍治療の各サイクルの初日にトロンボモジュリン0.06mg/kgを1サイクルあたり1回静脈内投与するための、該トロンボモジュリン。
〔14-2〕上記〔1〕~〔12〕に記載の特徴を有する上記〔14〕に記載のトロンボモジュリン。
〔15〕オキサリプラチンによる抗悪性腫瘍治療を受けるヒト癌患者における抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための方法であって、トロンボモジュリンをヒト癌患者に投与する工程を含む該方法であって、前記抗悪性腫瘍治療は、オキサリプラチンをヒト癌患者に静脈内投与し、その後休薬することを1サイクルとしてこれを繰り返す治療であり、前記抗悪性腫瘍治療の各サイクルの初日にトロンボモジュリン0.06mg/kgを1サイクルあたり1回静脈内投与するための、該方法。
〔15-2〕上記〔1〕~〔12〕に記載の特徴を有する上記〔15〕に記載の方法。
相同変異配列としては、対象とするペプチドのアミノ酸配列中、1つ又は複数のアミノ酸が置換、欠失、又は付加していてもよいペプチド配列が例示される。置換、欠失、又は付加していてもよいアミノ酸の数としては、1~40個が例示され、好ましくは1~20個、より好ましくは1~10個、さらに好ましくは1~5個、特に好ましくは1~3個が例示される。また、相同変異配列としては、対象とするペプチドのアミノ酸配列中、一定以上の相同性を有するペプチド配列が例示される。一定以上の相同性としては、80%以上が例示され、好ましくは85%以上、より好ましくは90%以上、さらに好ましくは95%以上、特に好ましくは98%以上の相同性が例示される。
トロンボモジュリン活性としては、(1)トロンビンと選択的に結合して(2)トロンビンによるプロテインCの活性化を促進する作用が例示される。また、(3)トロンビンによる凝固時間を延長する作用、(4)トロンビンによる血小板凝集を抑制する作用、又は(5)抗炎症作用が例示される。トロンボモジュリン活性としては、上記(1)及び(2)の作用を有し、さらに上記(1)~(4)の作用を有していることが例示される。また、別の態様として、(1)~(5)の作用を全て有していることが例示される。
トロンボモジュリンのトロンビンとの結合作用は、例えば、Thrombosis and Haemostasis 1993 70(3):418-422やThe Journal of Biological Chemistry 1989 264(9):4872-4876を初めとする各種の公知文献に記載の試験方法により確認できる。トロンビンによるプロテインCの活性化を促進する作用は、例えば、特開昭64-6219号公報を初めとする各種の公知文献に明確に記載された試験方法によりプロテインCの活性化を促進する作用の活性量やその有無を容易に確認できるものである。また、トロンビンによる凝固時間を延長する作用、及び/又はトロンビンによる血小板凝集を抑制する作用についても同様に容易に確認できる。さらには、抗炎症作用についても、例えばBlood 2008 112:3361-3670、The Journal of Clinical Investigation 2005 115(5):1267-1274を初めとする各種の公知文献に記載の試験方法により確認できる。
一つの実施形態において、トロンボモジュリンとしては、配列番号1もしくは配列番号3における第19~516位、第19~515位、第17~516位、又は第17~515位の配列からなるペプチドが例示される。トロンボモジュリンは、配列番号1もしくは配列番号3における第19~516位、第19~515位、第17~516位、又は第17~515位の配列からなるペプチドの混合物である場合がある。
一つの実施形態において、トロンボモジュリンとしては、前記トロンボモジュリンであれば特に限定されないが、可溶性トロンボモジュリンが例示される。別の態様としては、ヒトトロンボモジュリンが例示される。さらに別の態様としては、ヒト可溶性トロンボモジュリンが例示される。さらに別の態様としては、トロンボモデュリン アルファ(遺伝子組換え)が例示される。トロンボモデュリン アルファ(遺伝子組換え)は、日本において医薬品としての承認を受けているリコモジュリン(登録商標)の有効成分である。トロンボモデュリン アルファ(遺伝子組換え)は、ART-123と呼ばれることもある。
可溶性トロンボモジュリンとしては、界面活性剤の非存在下で水に可溶なトロンボモジュリンが例示される。可溶性トロンボモジュリンの溶解性の好ましい例示としては、水、例えば注射用蒸留水に対して(トリトンX-100やポリドカノール等の界面活性剤の非存在下、通常は中性付近にて)、1mg/mL以上、または10mg/mL以上が挙げられ、好ましくは15mg/mL以上、または17mg/mL以上が挙げられ、さらに好ましくは20mg/mL以上、25mg/mL以上、または30mg/mL以上が例示され、特に好ましくは60mg/mL以上が挙げられ、場合によっては、80mg/mL以上、または100mg/mL以上がそれぞれ挙げられる。可溶性トロンボモジュリンが溶解し得たか否かを判断するに当たっては、溶解した後に、例えば白色光源の直下、約1000ルクスの明るさの位置で、肉眼で観察した場合に、澄明であって、明らかに認められるような程度の不溶性物質を含まないことが端的な指標となるものと理解される。また、濾過して残渣の有無を確認することもできる。
トロンボモジュリンの分子量としては、分子量の上限としては100,000以下が好ましく、90,000以下がより好ましく、80,000以下がさらに好ましく、70,000以下が特に好ましく、分子量の下限としては、50,000以上がさらに好ましく、60,000以上が特に好ましい。可溶性トロンボモジュリンの分子量は、たん白質の分子量を測定する通常の方法で容易に測定が可能であるが、質量分析法にて測定することが好ましく、MALDI-TOF-MS法がより好ましい。目的の範囲の分子量の可溶性トロンボモジュリンを取得するためには、後述の通り、可溶性トロンボモジュリンをコードするDNAをベクターにより宿主細胞にトランスフェクトして調製された形質転換細胞を培養することにより取得される可溶性トロンボモジュリンをカラムクロマトグラフィー等により分画することで取得することができる。
トロンボモジュリンは後述の通り、これらのペプチドをコードするDNA(例えば、配列番号2または配列番号4等の塩基配列)をベクターにより宿主細胞にトランスフェクトして調製された形質転換細胞より取得することができる。
後述の通り、トロンボモジュリンの取得は遺伝子操作により取得することに限定されるものではないが、遺伝子操作により取得する場合には、発現に際して用いることができるシグナル配列としては、配列番号1の第1~18位のアミノ酸配列をコードする塩基配列、配列番号1の第1~16位のアミノ酸配列をコードする塩基配列、その他公知のシグナル配列、例えば、ヒト組織プラスミノゲンアクチベータのシグナル配列を利用することができる(国際公開88/9811号公報)。
一つの実施形態におけるトロンボモジュリンの生産方法は、上記の方法に限定されるものではなく、例えば、尿や血液、その他体液等から抽出精製することでも可能であるし、またトロンボモジュリンを生産する組織またはこれら組織培養液等から抽出精製することも、また必要によりさらに蛋白分解酵素により切断処理することも可能である。
また、一つの実施形態において、トロンボモジュリンは、術後再発抑制を目的とした補助化学療法においても使用することができる。さらには、再発癌又は転移癌のヒト癌患者にも投与することができる。
一つの実施形態において、抗悪性腫瘍剤による治療としては、オキサリプラチンをヒト癌患者に静脈内投与し、その後休薬することを1サイクルとしてこれを繰り返す場合、オキサリプラチンをヒト癌患者に1~6回静脈内投与し、その後、少なくとも6日間休薬することを1サイクルとしてこれを繰り返す治療が例示される。また、オキサリプラチンは、例えばエルプラット(登録商標)添付文書又はEloxatinラベルに記載の使用方法で使用することができる。
体表面積(m2)=身長(cm)0.725×体重(kg)0.425×0.007184
(a)ヒト癌患者に、オキサリプラチンとして80~90mg/m2(体表面積)を1日1回静脈内投与し、少なくとも13日間休薬する。これを1サイクルとして投与を繰り返す。
(b)ヒト癌患者に、オキサリプラチンとして85mg/m2(体表面積)を1日1回静脈内投与し、少なくとも13日間休薬する。これを1サイクルとして投与を繰り返す。
(c)ヒト癌患者に、オキサリプラチンとして90~110mg/m2(体表面積)を1日1回静脈内投与し、少なくとも13日間休薬する。これを1サイクルとして投与を繰り返す。
(d)ヒト癌患者に、オキサリプラチンとして100mg/m2(体表面積)を1日1回静脈内投与し、少なくとも20日間休薬する。これを1サイクルとして投与を繰り返す。
(f)ヒト癌患者に、オキサリプラチンとして130mg/m2(体表面積)を1日1回静脈内投与し、少なくとも20日間休薬する。これを1サイクルとして投与を繰り返す。
一つの実施形態において、オキサリプラチンは作用機序の異なる複数の抗悪性腫瘍剤と組み合わせて投与することができる。例えば、オキサリプラチンはFOLFOX療法により投与することができる。FOLFOX療法は、オキサリプラチンをフルオロウラシル及びレボホリナートと組み合わせて行う抗悪性腫瘍治療である。FOLFOX療法は、投与方法によって、例えば、FOLFOX2、FOLFOX3、FOLFOX4、FOLFOX6、mFOLFOX6、FOLFOX7、又はmFOLFOX7に分類される。また、オキサリプラチンはXELOX療法(CapeOX療法)、FOLFOXIRI療法、FOLFIRINOX療法、又はSOX療法により投与することができる。XELOX療法は、オキサリプラチンをカペシタビンと組み合わせて行う抗悪性腫瘍治療である。FOLFOXIRI療法又はFOLFIRINOX療法は、オキサリプラチンを、イリノテカン塩酸塩水和物、フルオロウラシル、及びレボホリナートと組み合わせて行う抗悪性腫瘍治療である。SOX療法は、オキサリプラチンをS-1(テガフール・ギメラシル・オテラシルカリウム配合剤)と組み合わせて行う抗悪性腫瘍治療である。
また、一つの実施形態において、オキサリプラチンは、制吐剤又は抗アレルギー剤と共に投与することができる。
一つの実施形態において、トロンボモジュリンは、抗悪性腫瘍剤の投与開始前に投与することができる。また、抗悪性腫瘍剤の投与開始後に投与することもできる。さらに、トロンボモジュリンと抗悪性腫瘍剤の投与を同時に開始することもできる。
一度に所望の量を投与する方法(静脈内急速投与)は投与時間が短い点で好ましい。一度に投与する場合には、注射器での投与に要する時間に通常幅があるが、投与に要する時間としては、投与する液量にもよるが、5分以下が例示され、3分以下が好ましく、2分以下がより好ましく、1分以下がさらに好ましく、30秒以下が特に好ましい。また下限としては特に限定されないが、1秒以上が好ましく、5秒以上がより好ましく、10秒以上がさらに好ましい。投与量は上記の好ましい投与量であれば特に限定されない。また、点滴静脈内投与はトロンボモジュリンの血中濃度を一定に保つことが容易な点で好ましい。
なお、リコモジュリン(登録商標)添付文書「薬物動態」1.(2)の図に記載の通り、トロンボモデュリン アルファ(遺伝子組換え)0.06mg/kgは380U/kgに相当することがわかる。すなわち、トロンボモジュリン「0.06mg/kg」は、「380U/kg」と読み替えることができる場合がある。
配列番号1:ART-123の生産に用いた遺伝子がコードするアミノ酸配列
配列番号2:配列番号1のアミノ酸配列をコードする塩基配列
配列番号3:ART-123Mの生産に用いた遺伝子がコードするアミノ酸配列
配列番号4:配列番号3のアミノ酸配列をコードする塩基配列
配列番号5:部位特異的変異を行う際に使用する変異用合成DNA
<トロンボモジュリンの取得>
上記の方法、すなわち、配列番号1のアミノ酸配列をコードするDNA(具体的には、配列番号2の塩基配列よりなる)を、チャイニーズハムスター卵巣(CHO)細胞にトランスフェクションして、この形質転換細胞の培養液より前述した定法の精製法にて、50mmol/L NaClを含む20mmol/Lリン酸塩緩衝液(pH7.3)で活性画分を回収した高純度精製品を取得した。さらに限外濾過を行って濃度が11.2mg/mLのトロンボモジュリン(ART-123)溶液を取得した。
<添加剤溶液調製>
10Lのステンレス製容器に、塩酸アルギニン(味の素社製)480gを量り入れ、注射用水を5L加えて溶解した。1mol/L水酸化ナトリウム溶液を添加して、pHを7.3に調整した。
上記添加剤溶液全量を20Lのステンレス製容器に入れ、上記得られたART-123溶液2398mL(可溶性トロンボモジュリンのたん白質量として26.88gに相当。ただし12%過量仕込み。)加え混合攪拌した。さらに注射用水を加えて全量を12Lとして均一に混合撹拌した。この薬液を、孔径が0.22μmのフィルター(ミリポア製MCGL10S)で濾過滅菌した。濾過液を1mLずつバイアルに充填し、ゴム栓を半打栓した。
凍結乾燥→窒素充填→ゴム栓全打栓→キャップ巻締めの順で以下の条件にて凍結乾燥工程を行い、1容器中に可溶性トロンボモジュリン2mg、塩酸アルギニン40mgを含むART-123含有製剤を得た。
<凍結乾燥条件>
予備冷却(15分かけて室温から15℃)→ 本冷却(2時間かけて15℃から-45℃)→ 保持(2時間 -45℃)→ 真空開始(18時間 -45℃)→ 昇温(20時間かけて-45℃から25℃)→ 保持(15時間25℃)→ 昇温(1時間かけて25℃から45℃)→ 保持(5時間45℃)→ 室温(2時間かけて45℃から25℃)→ 復圧窒素充填(-100mmHgまで)→ 全打栓 → キャップ巻締め
配列番号3のアミノ酸配列をコードするDNA(具体的には、配列番号4の塩基配列よりなる)を、チャイニーズハムスター卵巣(CHO)細胞にトランスフェクションして、この形質転換細胞の培養液より前述した定法の精製法にて精製されたトロンボモジュリン(以下、ART-123Mと略すことがある)溶液を取得し、上記と同様の方法によりART-123Mの凍結乾燥製剤を取得する。
<試験方法>
根治切除(R0手術)後、病理ステージIIまたはIII結腸癌患者に、オキサリプラチンを含む術後補助化学療法を実施する際のオキサリプラチン誘発性末梢神経障害発症に対するART-123の有効性および安全性を検討するためにプラセボ対照の試験を行った。
オキサリプラチンを含む術後補助化学療法はmFOLFOX6法(オキサリプラチンとして85mg/m2(体表面積) を1日1回静脈内に2時間で点滴投与し、少なくとも13日間休薬する。これを1サイクルとして投与を繰り返す)とし、12サイクル実施した。被験者はプラセボ群、ART-123 1回投与群、ART-123 3回投与群の3群にランダムに割り付けた。プラセボ群では各サイクルの1日目、2日目および3日目にプラセボを投与し、ART-123 1回投与群では、各サイクルの1日目にART-123 0.06 mg/kg、2日目、3日目にプラセボを投与し、ART-123 3回投与群では、各サイクルの1日目、2日目および3日目にART-123 0.06 mg/kgを投与した。ART-123あるいはプラセボの投与は、1日目はオキサリプラチンの投与2時間~30分前に治験薬の投与を開始し、30分間点滴静脈内投与によりオキサリプラチン投与開始前に治験薬の投与を終了した。2日目、3日目は1日目と可能な限り同一時間帯にART-123あるいはプラセボの投与を開始し、30分間点滴静脈内投与した。
1.末梢神経障害の症状軽減効果
表1に治験薬投与開始から治験完了までに評価したFACT/GOG-NTX-12の投与群別の最小二乗平均の推移およびプラセボ群とART-123 1回投与群または3回投与群との差を示した。48点-患者評価点を評点とした。12サイクル時のART-123群の点数はいずれもプラセボ群よりも高く、ART-123は末梢神経障害の症状を軽減した。また、ART-123 1回投与群はART-123 3回投与群に比べ末梢神経障害の症状軽減効果が大きかった。
また、NRSによる手と足の痛みの評価を行ったところ、ART-123 1回投与群はART-123 3回投与群に比べ鎮痛効果が大きかった。
表2に治験薬投与開始から治験完了までに評価したNCI-CTCAE(末梢性感覚ニューロパチー)の投与群別のGrade2以上累積発現割合(各サイクルまでに1度でもGrade2以上を発現した症例の割合)およびプラセボ群とART-123 1回投与群または3回投与群との差を示した。12サイクル時のART-123群のGrade2以上累積発現割合はいずれもプラセボ群よりも低く、ART-123は末梢神経障害の発症を抑制した。また、ART-123 1回投与群はART-123 3回投与群に比べ末梢神経障害の発症抑制効果が大きかった。
表3に治験薬投与開始から治験完了までに評価したNCI-CTCAE(末梢性運動ニューロパチー)の投与群別のGrade2以上累積発現割合(各サイクルまでに1度でもGrade2以上を発現した症例の割合)およびプラセボ群とART-123 1回投与群または3回投与群との差を示した。12サイクル時のART-123群のGrade2以上累積発現割合はいずれもプラセボ群よりも低く、ART-123は末梢神経障害の発症を抑制した。また、ART-123 1回投与群はART-123 3回投与群に比べ末梢神経障害の発症抑制効果が大きかった。
表4に投与群別に治験薬投与開始から治験完了までのオキサリプラチン総投与量である累積投与量を示した。平均値、中央値のいずれもプラセボ群に比較してART-123 1回投与群、3回投与群ともにオキサリプラチンの累積投与量が多かった。
表5に治験薬投与開始から治験完了までに発現した有害事象について、投与群別に治験薬との関連有無、重篤度、出血関連の有害事象ごとに発現例数、発現割合の集計結果およびプラセボ群とART-123 1回投与群または3回投与群との差を示した。有害事象の発現割合は、治験薬との関連有無、重篤度および出血との関連を問わず、いずれもプラセボ群と比べてART-123 1回投与群および3回投与群で顕著な差は認められず、安全に投与できることが確認された。
抗悪性腫瘍剤による末梢神経障害では、抗悪性腫瘍剤の投与を繰り返すことで末梢神経障害の症状が発症・悪化し、抗悪性腫瘍剤による治療の継続が困難になることが問題である。抗悪性腫瘍剤による治療で発生する末梢神経障害の症状軽減及び/又は発症抑制により、抗悪性腫瘍剤による治療を継続することが重要である。ART-123によるオキサリプラチン誘発性末梢神経障害の予防効果に関して、オキサリプラチン治療1サイクルに対するART-123の投与回数を検討するため、抗悪性腫瘍剤1回投与で誘起するラットオキサリプラチン誘発性末梢神経障害モデル評価系を構築した。オキサリプラチンを単回腹腔内投与してラットの足に発症する痛覚過敏(圧刺激痛覚閾値の低下)を末梢神経障害の指標とし、ART-123をオキサリプラチン投与日から1日1回投与することで、治療1サイクルの期間である14日間あるいは21日間痛覚過敏の発症を抑制しうる投与回数を検討した。
ラット静脈内投与の薬物動態学的パラメータは、ART-123を0.25mg/kgの用量で投与した場合、初期血漿中濃度(C0)が6.14μg/mL、半減期(t1/2β)は7.2時間である(リコモジュリン(登録商標)申請概要2.6.4.3.1.1項)。また、ヒトにART-123の臨床用法用量である0.06mg/kgを静脈内投与した場合の最高血漿中濃度は0.9~1.7μg/mL(リコモジュリン(登録商標)申請概要2.5.3.2.1項)であり、半減期は約20時間である(リコモジュリン(登録商標)申請概要2.5.3.3項)。これらの静脈内投与の比較では、ヒトとラットの半減期が大きく異なることから、ラット静脈内投与により、ヒトに近い血漿中濃度推移を達成することは困難であると考えられた。そこでラット腹腔内投与の薬物動態学的パラメータについて検討した。
7-8週齢のSprague Dawley系雄性ラットにART-123を1mg/kgの用量で、腹腔内投与し、経時的に血漿を取得した。血漿中濃度はELISA法で測定し、薬物速度論的パラメータはノンコンパートメントモデルにて解析した。
ART-123を1mg/kgの用量で腹腔内投与した場合の血漿中濃度推移から算出した最高血漿中濃度(Cmax)は5.47 μg/mL、最高血漿中濃度到達時間(tmax)は6.00 時間、半減期(t1/2)は14.1時間であった。
<試験方法>
(1)オキサリプラチン誘発性末梢神経障害モデルラットの作製
実験動物として7週齢のSprague Dawley系雄性ラットを用い、ラットにオキサリプラチンを6mg/kgの用量で、腹腔内に単回投与して作製した。
(2)被験薬の投与
オキサリプラチンを投与したラットに、ART-123を、オキサリプラチン投与日から1日1回の頻度で合計7回腹腔内投与した。その際の投与用量は0.3mg/kg、1mg/kg、又は10mg/kgとした(それぞれ0.3mg/kg、1mg/kg、又は10mg/kg群)。また陰性対照として媒体を1日1回、7日間腹腔内投与した(媒体群)。
上記ラットについて、Randall LO.ら、Arch.Int.Pharmacodyn.Ther.1957.111,409-419に記載の足圧痛法(Randall-Selitto test)に準じて測定した。すなわち、右後肢足を圧刺激鎮痛効果測定装置で次第に加圧して、逃避反応を示したときの圧力を圧刺激逃避閾値とした。
ART-123の作用に関しては、オキサリプラチン投与後14日目および21日目の圧刺激逃避閾値について統計処理を実施した。媒体群を対照として、0.3mg/kg、1mg/kg、および10mg/kg群の圧刺激逃避閾値について、パラメトリックWilliams検定(上昇方向)を有意水準片側2.5%以下で行った(図1中の*、**:p<0.05、p<0.01)。また、媒体群のオキサリプラチン投与1日前とオキサリプラチン投与後14日目あるいは21日目の圧刺激逃避閾値について、対応のあるt検定を有意水準両側5%で行った(図1中の##:p<0.01)。
ラットでのART-123をオキサリプラチン投与当日から1日1回、7日間の予防的投与の結果を図1に示す。オキサリプラチン投与後14日目および21日目の対照群では、オキサリプラチン投与前日と比べて圧刺激逃避閾値が有意に低下しており、痛覚過敏が発症していた。ART-123投与群では媒体群で認められた圧刺激逃避閾値の低下を0.3mg/kgから用量依存的にかつ有意に抑制した。
<試験方法>
(1)オキサリプラチン誘発性末梢神経障害モデルラットの作製
上記試験2.と同様に、7週齢のSprague Dawley系雄性ラットを用い、ラットにオキサリプラチンを6mg/kgの用量で、腹腔内に単回投与して作製した。
ART-123 1回投与群として、オキサリプラチンを投与したラットに、オキサリプラチン投与日当日にART-123を1回、翌日及び翌々日に媒体をそれぞれ1回腹腔内投与した。ART-123 2回投与群として、オキサリプラチンを投与したラットに、オキサリプラチン投与当日及びその翌日にART-123をそれぞれ1回、翌々日に媒体をそれぞれ1回腹腔内投与した。ART-123 3回投与群として、オキサリプラチンを投与したラットに、オキサリプラチン投与当日、翌日、及び翌々日にART-123をそれぞれ1回腹腔内投与した。ART-123の投与用量は1mg/kgとした。また陰性対照として媒体を1日1回、3日間腹腔内投与した(媒体群)。
上記試験2.と同様に、右後肢足を圧刺激鎮痛効果測定装置で次第に加圧して、逃避反応を示したときの圧力を圧刺激逃避閾値とした。
(4)統計処理
ART-123の作用に関しては、オキサリプラチン投与後14日目および21日目の圧刺激逃避閾値について統計処理を実施した。媒体群を対照として、ART-123の1回、2回および3回投与群の圧刺激逃避閾値について、パラメトリックWilliams検定(上昇方向)を有意水準片側2.5%以下で行った(図2中の*、**:p<0.05、p<0.01)。また、媒体群のオキサリプラチン投与1日前とオキサリプラチン投与後14日目あるいは21日目の圧刺激逃避閾値について、対応のあるt検定を有意水準両側5%で行った(図2中の##:p<0.01)。
オキサリプラチン投与後14日目および21日目の対照群では、オキサリプラチン投与前日と比べて圧刺激逃避閾値が有意に低下しており、痛覚過敏が発症していた。ART-123を1mg/kgの用量でオキサリプラチン投与当日、翌日、及び翌々日にそれぞれ1回、合計3回投与した場合、 オキサリプラチン治療1サイクルである14日目あるいは21日目において痛覚過敏を有意に抑制した。一方、ART-123の投与がオキサリプラチン投与当日のみの1回の場合、 オキサリプラチン治療1サイクルである14日目又は21日目まで痛覚過敏の抑制を持続する効果が弱い又は認められなかった。結果を図2に示す。
Claims (12)
- オキサリプラチンによる抗悪性腫瘍治療を受けるヒト癌患者における抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬であって、前記抗悪性腫瘍治療は、オキサリプラチンをヒト癌患者に静脈内投与し、その後休薬することを1サイクルとしてこれを繰り返す治療であり、前記抗悪性腫瘍治療の各サイクルの初日にトロンボモジュリン0.06mg/kgを1サイクルあたり1回静脈内投与するための、トロンボモジュリンを有効成分として含有する該医薬。
- 前記抗悪性腫瘍治療におけるオキサリプラチン総投与量の低減を抑制するための請求項1に記載の医薬。
- 前記オキサリプラチンによる抗悪性腫瘍治療が、オキサリプラチン50~150mg/m2(体表面積)を1日1回1~3日間ヒト癌患者に静脈内投与し、その後少なくとも13日間休薬することを1サイクルとしてこれを繰り返す治療である請求項1又は2に記載の医薬。
- オキサリプラチンがFOLFOX療法により投与される請求項1~3のいずれか1項に記載の医薬。
- オキサリプラチンの投与開始前に前記トロンボモジュリン投与が開始される、請求項1~4のいずれか1項に記載の医薬。
- 大腸癌、膵癌、及び胃癌からなる群より選択される1種以上の癌を患った癌患者に投与される請求項1~5のいずれか1項に記載の医薬。
- 末梢神経障害が、末梢性運動神経障害又は末梢性感覚神経障害である請求項1~6のいずれか1項に記載の医薬。
- 前記トロンボモジュリンが可溶性トロンボモジュリンである請求項1~7のいずれか1項に記載の医薬。
- 前記トロンボモジュリンがヒトトロンボモジュリンである請求項1~7のいずれか1項に記載の医薬。
- 前記トロンボモジュリンが、下記(i-1)又は(i-2)のいずれかのアミノ酸配列をコードするDNAを宿主細胞にトランスフェクトして調製された形質転換細胞より取得されるペプチド(但し、(i-2)のアミノ酸配列をコードするDNAより取得されるペプチドである場合、該ペプチドはトロンボモジュリン活性を有する)である請求項1~7のいずれか1項に記載の医薬;
(i-1)配列番号1又は配列番号3のいずれかに記載のアミノ酸配列、又は
(i-2)上記(i-1)のアミノ酸配列の1つ又は複数のアミノ酸が置換、欠失、又は付加されたアミノ酸配列。 - 前記トロンボモジュリンが、下記(i-1)又は(i-2)のいずれかのアミノ酸配列を含むペプチドであって、該ペプチドがトロンボモジュリン活性を有するペプチドである請求項1~7のいずれか1項に記載の医薬;
(i-1)配列番号1又は配列番号3のいずれかに記載のアミノ酸配列における第19~516位のアミノ酸配列、又は
(i-2)上記(i-1)のアミノ酸配列の1つ又は複数のアミノ酸が置換、欠失、又は付加されたアミノ酸配列。 - 前記トロンボモジュリンがトロンボモデュリン アルファ(遺伝子組換え)である請求項1~9のいずれか1項に記載の医薬。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217008750A KR20210049143A (ko) | 2018-09-28 | 2019-09-27 | 항악성 종양제에 의한 말초 신경 장애의 증상 경감 및/또는 발증 억제를 위한 의약 |
CA3112679A CA3112679A1 (en) | 2018-09-28 | 2019-09-27 | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
JP2020549413A JP7245844B2 (ja) | 2018-09-28 | 2019-09-27 | 抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬 |
EP19865629.0A EP3858371A4 (en) | 2018-09-28 | 2019-09-27 | MEDICINE FOR RELIEVING SYMPTOMS OF PERIPHERAL NEUROPATHY CAUSED BY AN ANTICANCER MEDICINE AND/OR INHIBITING THE ONSET OF PERIPHERAL NEUROPATHY |
BR112021001716-0A BR112021001716A2 (pt) | 2018-09-28 | 2019-09-27 | medicamento para aliviar enfermidades e/ou suprimir o início de uma neuropatia periférica |
CN201980062954.6A CN112839669A (zh) | 2018-09-28 | 2019-09-27 | 用于减轻由抗恶性肿瘤剂引起的末梢神经障碍的症状和/或抑制其发病的药物 |
AU2019347406A AU2019347406B9 (en) | 2018-09-28 | 2019-09-27 | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
MX2021003288A MX2021003288A (es) | 2018-09-28 | 2019-09-27 | Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica. |
US16/657,507 US11497795B2 (en) | 2018-09-28 | 2019-10-18 | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
ZA2021/01882A ZA202101882B (en) | 2018-09-28 | 2021-03-19 | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
IL281818A IL281818A (en) | 2018-09-28 | 2021-03-25 | A drug for the relief of conditions and/or onset of peripheral neuropathy caused by an anti-malignant agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018183447 | 2018-09-28 | ||
JP2018-183447 | 2018-09-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/657,507 Continuation US11497795B2 (en) | 2018-09-28 | 2019-10-18 | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020067389A1 true WO2020067389A1 (ja) | 2020-04-02 |
Family
ID=69950738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/038066 WO2020067389A1 (ja) | 2018-09-28 | 2019-09-27 | 抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3858371A4 (ja) |
JP (1) | JP7245844B2 (ja) |
KR (1) | KR20210049143A (ja) |
CN (1) | CN112839669A (ja) |
AU (1) | AU2019347406B9 (ja) |
BR (1) | BR112021001716A2 (ja) |
CA (1) | CA3112679A1 (ja) |
IL (1) | IL281818A (ja) |
MX (1) | MX2021003288A (ja) |
TW (1) | TWI739164B (ja) |
WO (1) | WO2020067389A1 (ja) |
ZA (1) | ZA202101882B (ja) |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988009811A1 (en) | 1987-06-12 | 1988-12-15 | Novo-Nordisk A/S | Proteins and derivatives thereof |
JPS646219A (en) | 1987-01-08 | 1989-01-10 | Asahi Chemical Ind | Peptide having promoting action on activation of protein c by thrombin |
JPS6445398A (en) | 1987-08-13 | 1989-02-17 | Kowa Co | Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody |
JPH02255699A (ja) | 1989-03-28 | 1990-10-16 | Asahi Chem Ind Co Ltd | 新規血液抗凝固物質及びその製法 |
JPH0542920B2 (ja) | 1987-04-01 | 1993-06-30 | Mitsubishi Gas Chemical Co | |
JPH05213998A (ja) | 1990-08-03 | 1993-08-24 | Asahi Chem Ind Co Ltd | 新規なポリペプチド及びこれを有効成分とする 医薬組成物 |
JPH05310787A (ja) | 1992-05-01 | 1993-11-22 | Asahi Chem Ind Co Ltd | 新規なポリペプチド |
JPH06205692A (ja) | 1993-01-08 | 1994-07-26 | Asahi Chem Ind Co Ltd | 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法 |
JPH06321805A (ja) | 1993-03-16 | 1994-11-22 | Asahi Chem Ind Co Ltd | トロンボモジュリン組成物およびその変性防止方法 |
JPH07155176A (ja) | 1994-05-31 | 1995-06-20 | Asahi Chem Ind Co Ltd | トロンビンによるプロテインcの活性化を促進する作用を有するペプチドを含有する培養物 |
JPH083065A (ja) | 1994-04-20 | 1996-01-09 | Asahi Chem Ind Co Ltd | 肝臓障害に対する治療剤 |
JPH09110900A (ja) | 1995-10-24 | 1997-04-28 | Nippon Chem Res Kk | トロンボモジュリンの精製方法 |
JPH11341990A (ja) | 1998-03-30 | 1999-12-14 | Asahi Chem Ind Co Ltd | 高純度可溶性トロンボモジュリンの製造方法 |
JP2011178687A (ja) | 2010-02-26 | 2011-09-15 | Kochi Univ | 造血細胞移植に伴う疼痛の予防および/または治療剤 |
WO2013073545A1 (ja) | 2011-11-15 | 2013-05-23 | 旭化成ファーマ株式会社 | 敗血症の治療及び/又は改善のための医薬 |
WO2013179910A1 (ja) | 2012-05-31 | 2013-12-05 | 学校法人近畿大学 | 抗癌剤に起因する末梢性神経障害性疼痛の予防及び/又は治療剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090051777A (ko) * | 2006-10-06 | 2009-05-22 | 아사히 가세이 파마 가부시키가이샤 | 파종성 혈관내 혈액 응고 증후군의 치료 및/또는 개선제 |
JPWO2009028605A1 (ja) * | 2007-08-31 | 2010-12-02 | 国立大学法人九州大学 | 抗がん剤による末梢神経障害の予防又は軽減剤 |
-
2019
- 2019-09-27 AU AU2019347406A patent/AU2019347406B9/en active Active
- 2019-09-27 TW TW108135247A patent/TWI739164B/zh active
- 2019-09-27 MX MX2021003288A patent/MX2021003288A/es unknown
- 2019-09-27 KR KR1020217008750A patent/KR20210049143A/ko not_active Application Discontinuation
- 2019-09-27 WO PCT/JP2019/038066 patent/WO2020067389A1/ja active Application Filing
- 2019-09-27 CA CA3112679A patent/CA3112679A1/en active Pending
- 2019-09-27 BR BR112021001716-0A patent/BR112021001716A2/pt unknown
- 2019-09-27 JP JP2020549413A patent/JP7245844B2/ja active Active
- 2019-09-27 CN CN201980062954.6A patent/CN112839669A/zh active Pending
- 2019-09-27 EP EP19865629.0A patent/EP3858371A4/en active Pending
-
2021
- 2021-03-19 ZA ZA2021/01882A patent/ZA202101882B/en unknown
- 2021-03-25 IL IL281818A patent/IL281818A/en unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS646219A (en) | 1987-01-08 | 1989-01-10 | Asahi Chemical Ind | Peptide having promoting action on activation of protein c by thrombin |
JPH0542920B2 (ja) | 1987-04-01 | 1993-06-30 | Mitsubishi Gas Chemical Co | |
WO1988009811A1 (en) | 1987-06-12 | 1988-12-15 | Novo-Nordisk A/S | Proteins and derivatives thereof |
JPS6445398A (en) | 1987-08-13 | 1989-02-17 | Kowa Co | Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody |
JPH02255699A (ja) | 1989-03-28 | 1990-10-16 | Asahi Chem Ind Co Ltd | 新規血液抗凝固物質及びその製法 |
JPH05213998A (ja) | 1990-08-03 | 1993-08-24 | Asahi Chem Ind Co Ltd | 新規なポリペプチド及びこれを有効成分とする 医薬組成物 |
JPH05310787A (ja) | 1992-05-01 | 1993-11-22 | Asahi Chem Ind Co Ltd | 新規なポリペプチド |
JPH06205692A (ja) | 1993-01-08 | 1994-07-26 | Asahi Chem Ind Co Ltd | 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法 |
JPH06321805A (ja) | 1993-03-16 | 1994-11-22 | Asahi Chem Ind Co Ltd | トロンボモジュリン組成物およびその変性防止方法 |
JPH083065A (ja) | 1994-04-20 | 1996-01-09 | Asahi Chem Ind Co Ltd | 肝臓障害に対する治療剤 |
JPH07155176A (ja) | 1994-05-31 | 1995-06-20 | Asahi Chem Ind Co Ltd | トロンビンによるプロテインcの活性化を促進する作用を有するペプチドを含有する培養物 |
JPH09110900A (ja) | 1995-10-24 | 1997-04-28 | Nippon Chem Res Kk | トロンボモジュリンの精製方法 |
JPH11341990A (ja) | 1998-03-30 | 1999-12-14 | Asahi Chem Ind Co Ltd | 高純度可溶性トロンボモジュリンの製造方法 |
JP2011178687A (ja) | 2010-02-26 | 2011-09-15 | Kochi Univ | 造血細胞移植に伴う疼痛の予防および/または治療剤 |
WO2013073545A1 (ja) | 2011-11-15 | 2013-05-23 | 旭化成ファーマ株式会社 | 敗血症の治療及び/又は改善のための医薬 |
WO2013179910A1 (ja) | 2012-05-31 | 2013-12-05 | 学校法人近畿大学 | 抗癌剤に起因する末梢性神経障害性疼痛の予防及び/又は治療剤 |
JP2018095652A (ja) * | 2012-05-31 | 2018-06-21 | 学校法人近畿大学 | 抗癌剤に起因する末梢性神経障害性疼痛の予防及び/又は治療剤 |
Non-Patent Citations (18)
Title |
---|
"Biochemical Experimental Methods", vol. 23, 1990, JAPAN SCIENTIFIC SOCIETIES PRESS, article "Methods of Researches on Glycoprotein Sugar Chains" |
"Glycoprotein (Book 1", vol. 3, 1990, TOKYO KAGAKU DOJIN, article "Lecture of New Biochemical Experiments" |
"Tanpakushitsu/Koso no Kiso Jikken Ho (Fundamental Experimental Methods for Proteins and Enzymes", 1981 |
ANONYMOUS: "Oxaliplatin i.v. infusion 50mg 'SAWAI', Oxaliplatin i.v. infusion 100 mg 'SAWAI", PHARMACEUTICAL INTERVIEW FORM, 30 November 2014 (2014-11-30), pages 1 - 44, XP009526619 * |
BLOOD, vol. 112, 2008, pages 3361 - 3670 |
DUBOIS D.DUBOIS E.F., ARCH. INTERN. MED., vol. 17, 1916, pages 863 - 871 |
EMBO JOURNAL, vol. 6, 1987, pages 1891 - 1897 |
FOLIA PHARMACOLOGICA JAPONICA (NIPPON YAKURIGAKU ZASSHI, vol. 136, 2010, pages 275 - 279 |
GOMI K ET AL., BLOOD, vol. 75, 1990, pages 1396 - 1399 |
HERSHMAN ET AL.: "Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline", JOURNAL OF CLINICAL ONCOLOGY, 2014 |
J. BIOL. CHEM., vol. 264, 1989, pages 10351 - 10353 |
MULLIGAN R.C. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 78, 1981, pages 2072 - 2076 |
RANDALL LO ET AL., ARCH. INT. PHARMACODYN. THER., vol. 111, 1957, pages 409 - 419 |
S L MOLL, LINDLEY C, PESCATORE S, MORRISON D, TSURUTA K, MOHRI M, SERADA M, SATA M, SHIMIZU H, YAMADA K: "Phase I study of a novel recombinant human soluble thrombomodulin, ART- 123", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 2, 1 January 2004 (2004-01-01), pages 1745 - 1751, XP055702183, ISSN: 1528-7933 * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 9, 1989, pages 4872 - 4876 |
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 5, 2005, pages 1267 - 1274 |
THROMBOSIS AND HAEMOSTASIS, vol. 70, no. 3, 1993, pages 418 - 422 |
ZOLLER M.J. ET AL.: "Methods in Emzymology", vol. 100, 1983, ACADEMIC PRESS, pages: 468 - 500 |
Also Published As
Publication number | Publication date |
---|---|
AU2019347406A1 (en) | 2021-04-29 |
EP3858371A4 (en) | 2022-07-20 |
EP3858371A1 (en) | 2021-08-04 |
TW202023537A (zh) | 2020-07-01 |
BR112021001716A2 (pt) | 2021-04-27 |
IL281818A (en) | 2021-05-31 |
ZA202101882B (en) | 2022-09-28 |
CA3112679A1 (en) | 2020-04-02 |
AU2019347406B2 (en) | 2023-10-19 |
JPWO2020067389A1 (ja) | 2021-08-30 |
TWI739164B (zh) | 2021-09-11 |
KR20210049143A (ko) | 2021-05-04 |
MX2021003288A (es) | 2021-05-13 |
AU2019347406B9 (en) | 2023-11-16 |
JP7245844B2 (ja) | 2023-03-24 |
CN112839669A (zh) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6427284B2 (ja) | 抗癌剤に起因する末梢性神経障害性疼痛の予防及び/又は治療剤 | |
TW201945031A (zh) | 低ph藥物製劑 | |
KR101956585B1 (ko) | 면역글로불린과 c1-억제제를 사용하는 병용 치료요법 | |
JP2022540781A (ja) | 抗cd47/pd‐l1二重特異性抗体を含む製剤、その調製方法及び使用 | |
AU2011315466B2 (en) | Method for purification of complement Factor H | |
CN113453719A (zh) | 包含抗cd47抗体的制剂及其制备方法和用途 | |
JP2011178687A (ja) | 造血細胞移植に伴う疼痛の予防および/または治療剤 | |
WO2020067389A1 (ja) | 抗悪性腫瘍剤による末梢神経障害の症状軽減及び/又は発症抑制のための医薬 | |
US11497795B2 (en) | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent | |
WO2022111612A1 (zh) | 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途 | |
WO2023077924A1 (zh) | 一种抗胰腺癌的疫苗、及其医药用途 | |
WO2024092016A1 (en) | Cell targeting constructs and uses thereof | |
CA3158862A1 (en) | Polypeptide inhibitors of neutrophil elastase activity and uses thereof | |
KR20170118058A (ko) | 혈장 칼리크레인 및 인자 xii에 대한 이중특이성 항체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19865629 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021001716 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 3112679 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020549413 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20217008750 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112021001716 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210129 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021107897 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2019347406 Country of ref document: AU Date of ref document: 20190927 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019865629 Country of ref document: EP Effective date: 20210428 |